We recently issued a press release on study findings, published in Cornea, 2017, showing that the use of cryopreserved amniotic membrane reduces recurrence rates after pterygium surgery.
In this retrospective review, 556 eyes representing 535 patients (291 males 244 females), who had pterygium excision (527 primary, 29 recurrent) were treated with adjunctive cryopreserved amniotic membrane (Amniograft®, Bio-Tissue, Inc. Miami FL). After 17.3 ± 0.8 months (range 6-74 months), corneal recurrence occurred in only 20 eyes (3.6%) and conjunctival recurrence in 12 (2.2%) eyes, for a total recurrence rate of 5.8%.
Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer, TissueTech said, “This recent study is further evidence that cryopreserved amniotic membrane provides an excellent alternative to conjunctival autograft to reduce surgery time, save conjunctiva, promote faster recovery and reduce the pterygium recurrence. The unique extracellular matrix components, including Heavy Chain Hyaluronic Acid/Pentraxin-3 complex (HC-HA/PTX3), that are found in cryopreserved amniotic membrane have been shown to orchestrate regenerative healing and suppress pain associated with inflammation. In turn, this can expedite patient recovery and help achieve superior cosmetic outcomes.”
Amniograft is manufactured using Bio-Tissue’s proprietary CryoTek® technology, which has been proven to preserve the innate biological and structural properties of the amniotic membrane matrix. The components of this matrix have been demonstrated to support regenerative healing.
Pterygium surgery with Amniograft is simpler and shorter compared with conjunctival autograft, as it eliminates the need for preparing an autograft of sufficient quality and thinness for optimal grafting.